...All right. Good evening, everyone. Thanks for coming today. I'm Nadim Ahmed, CEO of Cullinan Therapeutics, and we're looking forward to discussing the results of the REZILIENT1 study that were presented today in an oral presentation this morning at the main ASCO session. At the same time, we're also looking forward to the promise of zipalertinib in patients with EGFR exon 20 mutations, and I think there's a tremendous role that this therapy can play and you'll hear about it throughout the evening. This slide contains our disclosures. During this event management will be making certain forward-looking statements, so you should reference our SEC filings, specifically the risk factors for additional uncertainties that may cause actual results to differ. And now that we've got that one out of the way, let's focus back on the program. And so this evening I'm pleased to be joined by Jeff Jones, our Chief Medical Officer, as well as Dr. Danny Nguyen, Assistant Clinical Professor from the City...
